Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790296 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue
A Phase 2 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00790296: Clinical Trial Phase 2 study, sponsored by UConn Health.
NCT00790296 is a Phase 2 study that was terminated before completion, run by UConn Health. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790296, a Phase 2 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.
Primary Outcome
1 to 100 scale with 1 referring to No Energy and 100 referring to Normal Energy.
Interventions
- DRUG Placebo
- DRUG Thyrotropin releasing hormone (TRH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Why NCT00790296 stopped before completion
NCT00790296 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00790296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00790296 about?
NCT00790296 is a clinical study titled "Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue". The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.
What is the current status of trial NCT00790296?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2006-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00790296?
The interventions under investigation include: Placebo (DRUG), Thyrotropin releasing hormone (TRH) (DRUG).
Who is sponsoring clinical trial NCT00790296?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00790296's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia